PureTech Health PLC PDMR Notification RSU Vesting
06 3월 2024 - 4:00PM
RNS Regulatory News
RNS Number : 6972F
PureTech Health PLC
06 March 2024
6
March 2024
PureTech Health
plc
PDMR
Notifications
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to
new classes of medicine to change the lives of patients with
devastating diseases, announces that
awards of restricted share units ("RSUs") granted by PureTech on 21 July
2021 to certain directors and other persons discharging managerial
responsibilities ("PDMRs")
pursuant to its Performance Share Plan ("PSP") vested on 4 March 2024
following satisfaction of performance conditions
measured over the three year period to 31 December
2023.
Each PDMR received vested ordinary
shares (after deduction of shares for payroll taxes) on 5 March
2024. The market price per ordinary share
in the Company used to calculate the amount payable to the PDMRs
and the amount of shares to be issued to PDMRs was 200 pence, being
the average closing price of the Company's shares over the
three-trading day period immediately preceding the settlement, and
the exchange rate used to calculate the cash payment and amount of
share settlement was £1: $1.26.
The Company's total issued ordinary
share capital is 289,468,159 shares after the share issuance to the
PDMRs, 19,259,058 shares of which are held in treasury by the
Company.
PDMR Notification
The information contained in the below notification is
disclosed in accordance with Article 19 of the EU Market Abuse
Regulation.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Daphne Zohar
Bharatt Chowrira
Eric Elenko
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Daphne Zohar - Chief Executive
Officer
Bharatt Chowrira - President and
Chief Business, Financial and Operating Officer
Eric Elenko - Chief Innovation and
Strategy Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
PureTech Health plc
|
|
b)
|
LEI
|
213800LVPDNO2Z9T9I39
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
|
Ordinary Shares of PureTech Health plc
ISIN GB00BY2Z0H74
|
|
|
|
b)
|
Nature of the transaction
|
Issuance of ordinary shares in net settlement of certain
vested RSUs under the PureTech Health Performance Share Plan, after
retentions in respect of payroll taxes.
|
|
c)
|
Price(s) and volume(s)
|
|
Recipient
|
Price
|
Amount
|
|
Daphne Zohar
|
0.01
GBP
|
148,482
ordinary shares
|
|
Bharatt Chowrira
|
0.01
GBP
|
59,287
ordinary shares
|
|
Eric Elenko
|
0.01
GBP
|
51,591
ordinary shares
|
|
|
d)
|
Aggregated information
|
|
Price
|
Aggregate
Volume
|
|
0.01 GBP
|
259,360 ordinary shares
|
|
|
e)
|
Date of the transaction
|
5 March 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
(XLON)
|
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded
Entities. PureTech's R&D engine has resulted in the
development of 28 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received
both US FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various
indications and stages of clinical development, including
registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates
were initially identified or discovered and then advanced by
the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUPUCCWUPCGAA
Puretech Health (LSE:PRTC)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Puretech Health (LSE:PRTC)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
